| scholarly article | Q13442814 |
| P50 | author | Benedetto Vitiello | Q92372542 |
| P2860 | cites work | A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder | Q46864359 |
| Safety and tolerability of methylphenidate in preschool children with ADHD. | Q46901785 | ||
| Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). | Q46917104 | ||
| Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height | Q47176352 | ||
| Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems | Q47242035 | ||
| Effects of stimulants on Hispanic boys' height and weight | Q47304719 | ||
| Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder | Q47339143 | ||
| Growth deficits and attention-deficit/hyperactivity disorder revisited: impact of gender, development, and treatment | Q47937714 | ||
| Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis | Q48464565 | ||
| Stimulant treatment over 5 years: effects on growth | Q50779918 | ||
| Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder | Q51935749 | ||
| National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment | Q51941986 | ||
| Depression of Growth in Hyperactive Children on Stimulant Drugs | Q54528350 | ||
| Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? | Q55066793 | ||
| Does Prolonged Therapy With a Long-Acting Stimulant Suppress Growth in Children With ADHD? | Q57400200 | ||
| Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-up | Q58822742 | ||
| Sudden cardiac death: definitions and causes | Q69535056 | ||
| Growth hormone, prolactin, and growth responses in hyperkinetic males treated with d-amphetamine | Q70731339 | ||
| Growth hormone and prolactin secretion in adults and hyperactive children: Relation to methylphenidate serum levels | Q71053555 | ||
| Prolactin, growth hormone and growth responses in boys with attention deficit disorder and hyperactivity treated with methylphenidate | Q71261460 | ||
| Growth of hyperactive children on maintenance regimen of methylphenidate | Q71678050 | ||
| Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children | Q72614488 | ||
| A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD | Q73256558 | ||
| Combining methylphenidate and clonidine: a clinically sound medication option | Q77406042 | ||
| AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs | Q78090065 | ||
| Effects of long-term psychostimulant medication on growth of children with ADHD | Q81849518 | ||
| Recent trends in stimulant medication use among U.S. children | Q83058769 | ||
| Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder | Q28189803 | ||
| Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder | Q28249894 | ||
| ADHD drugs and cardiovascular risk | Q28302969 | ||
| Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter | Q28504671 | ||
| Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial | Q32041811 | ||
| Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. | Q32041828 | ||
| Abuse and toxicity of methylphenidate | Q33958835 | ||
| Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature | Q33963472 | ||
| Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults | Q34113187 | ||
| The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder | Q34529904 | ||
| Slowing of growth in height and weight on stimulants: a characteristic pattern | Q35091100 | ||
| Cardiovascular effects of atomoxetine in children, adolescents, and adults | Q35178553 | ||
| Growth on stimulant medication; clarifying the confusion: a review | Q35284563 | ||
| Stimulants and sudden death: what is a physician to do? | Q36584865 | ||
| Sudden death from cardiac causes in children and young adults | Q40968766 | ||
| Growth of Hyperactive Children Treated With Methylphenidate | Q41437698 | ||
| Side Effects of Methylphenidate and Dexamphetamine in Children With Attention Deficit Hyperactivity Disorder: A Double-blind, Crossover Trial | Q42547460 | ||
| Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth | Q42657372 | ||
| Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder | Q42692616 | ||
| Short-term cardiovascular effects of methylphenidate and adderall | Q43605125 | ||
| Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder | Q43753661 | ||
| Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children? | Q43899146 | ||
| Methylphenidate-related growth impairment | Q43996151 | ||
| Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma | Q44317525 | ||
| Daily methylphenidate use slows the growth of children: a community based study. | Q44525112 | ||
| Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study | Q44717857 | ||
| Growth and sexual maturation during long-term treatment with risperidone | Q44879559 | ||
| Growth rebound after termination of stimulant drugs | Q44896389 | ||
| Methylphenidate and growth in hyperactive children. A controlled withdrawal study | Q45222611 | ||
| Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder | Q45260575 | ||
| A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder | Q45287375 | ||
| The global market for ADHD medications. | Q46300840 | ||
| Stimulant-related reductions of growth rates in the PATS. | Q46387671 | ||
| Height, weight, IGF-I, IGFBP-3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment | Q46408333 | ||
| Atomoxetine ingestions in children: a report from poison centers | Q46471327 | ||
| Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder | Q46581198 | ||
| ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study | Q46713659 | ||
| Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children | Q46719438 | ||
| Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. | Q46778584 | ||
| Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity | Q46794939 | ||
| The effect of chronic methylphenidate administration on tooth maturation in a sample of Caucasian children | Q46827950 | ||
| Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. | Q46848196 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| attention deficit hyperactivity disorder | Q181923 | ||
| attention | Q6501338 | ||
| P304 | page(s) | 459-74, xi | |
| P577 | publication date | 2008-04-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Child and Adolescent Psychiatric Clinics of North America | Q15749262 |
| P1476 | title | Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function | |
| P478 | volume | 17 |
| Q37380302 | "A massive long way": interconnecting histories, a "special child," ADHD, and everyday family life |
| Q24632726 | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD |
| Q51778456 | A compound herbal preparation (CHP) in the treatment of children with ADHD: a randomized controlled trial |
| Q24623713 | A practical guide to the therapy of narcolepsy and hypersomnia syndromes |
| Q42051054 | ADHD stimulants and their effect on height in children |
| Q34675680 | Adverse reactions of Methylphenidate in children with attention deficit-hyperactivity disorder: Report from a referral center |
| Q51805679 | Attention-Deficit/Hyperactivity Disorder |
| Q34461113 | Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? |
| Q28260681 | Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder |
| Q42671264 | Cardiovascular Safety of Stimulant Medications for Pediatric Attention-Deficit Hyperactivity Disorder |
| Q39193665 | Chondrocyte proliferation, viability and differentiation is declined following administration of methylphenidate utilized for the treatment of attention-deficit/hyperactivity disorder |
| Q34538107 | Comorbidities in ADHD children treated with methylphenidate: a database study |
| Q44805851 | Dose-Dependent Raynaud's Phenomenon Developing from Use of Atomoxetine in a Girl |
| Q55428656 | Effects of Atomoxetine on Height and Weight in Korean Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review. |
| Q21202070 | Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies |
| Q64238394 | Increased arterial pressure in mice with overexpression of the ADHD candidate gene calcyon in forebrain |
| Q38049859 | Management of Psychotropic Medication Side Effects in Children and Adolescents |
| Q24198192 | Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Q22061981 | Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) |
| Q33474263 | Methylphenidate has positive hypocholesterolemic and hypotriglyceridemic effects: new data |
| Q33162642 | Norepinephrine transporter variant A457P knock-in mice display key features of human postural orthostatic tachycardia syndrome |
| Q33571104 | Novel and functional norepinephrine transporter protein variants identified in attention-deficit hyperactivity disorder |
| Q22252568 | Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management |
| Q47855139 | Parents' Perspectives About Factors Influencing Adherence to Pharmacotherapy for ADHD. |
| Q38235204 | Pharmacological management of narcolepsy and cataplexy in pediatric patients |
| Q37833757 | Pharmacotherapy for Child and Adolescent Attention-deficit Hyperactivity Disorder |
| Q37700662 | Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants. |
| Q38060572 | Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. |
| Q30451303 | Safety of stimulant treatment in attention deficit hyperactivity disorder: part II. |
| Q42157991 | The Medical and Economic Burden of Narcolepsy: Implications for Managed Care |
| Q36220220 | The effects of long-term medication on growth in children and adolescents with ADHD: an observational study of a large cohort of real-life patients |
| Q60683248 | Trastorno por déficit de atención con hiperactividad en la infancia y la adolescencia: del constructo social al calvinismo farmacológico |
| Q46289405 | Update on adult attention-deficit/hyperactivity disorder |
| Q47982076 | Update on therapy for narcolepsy |
Search more.